If patents are “for the weak,” as Elon Musk claims, why is he patenting his inventions? In this article, we’ll take an in-depth look at Musk’s IP strategy and patent portfolios: ow.ly/reFw50LWK8X #ElonMusk #Tesla #patentportfolio

Every year IPBC Global brings together the people shaping the future of IP. This year, Patsnap's very own Emma Duran is moderating Women in IP Live, a panel with Charu Kurani (Lead Counsel, Innovation and Thought Leadership at Airbnb), Laura Quatela (Board Member and former CLO at Lenovo), and Kathi Vidal (Partner at Winston Taylor). The women driving IP forward deserve a bigger stage. This is one of them. If you're heading to San Diego June 15-17, this one's worth your time. Comment below if you'll be attending. 👇 #WomenInIP #IPBCGlobal #IP #Innovation #IAM

The AI productivity conversation has a blind spot: the human operating system. 👤 AI compounds exponentially. Human biology doesn't. And the teams burning through their people chasing the machine won't be the ones still winning in 2030. Our co-founder Ray Chohan makes the case in Built In: automate routine cognitive work ruthlessly, then protect the mental bandwidth no API can replace. This isn't about slowing down. It's about building the infrastructure that makes sustained speed possible.⚡ Read the full story: bit.ly/4ocinkY #Burnout #AI #Employer #Patsnap

Our 2026 R&D Benchmark Report is making the rounds. 200 senior R&D leaders. Nine industries. The data on waste, AI and the race to market is now out. Full story at the link below. 👇 bit.ly/4v0h9vV #RandD #Innovation #AI #ArtificialIntelligence #Research

Today we're releasing the 2026 R&D Benchmark Report: Waste, AI and the Race to Market. 🚀 We surveyed 200 senior R&D leaders at organizations spending $50M annually. What they shared was candid. 73% say half or fewer of their projects ever reach market. 37% are spending up to 40% of their budget on work that never launches. 92% are using AI. And yet nearly half say better intelligence access would still be their biggest productivity gain. The report breaks down where the waste is coming from, why the intelligence gap persists, and what the highest-performing teams are doing differently. 💡 Get your copy here: bit.ly/3PZoe0s #RD #Innovation #BenchmarkReport #IPStrategy #AIinRD #Patsnap #2026RandDBenchmark

Biological sequence searches can get messy fast, especially when you’re juggling fragmented workflows, rigid tools, and the pressure to connect sequences to IP, without missing a single insight. Join us for Bio Essentials: Speed Up Sequence Analysis & Discover What Matters Faster. 📆 09 June, 2026 🕐 10:00 AM EST | 3:00 PM BST In this session, we’ll show you how to move beyond slow, manual workflows. Learn how to search sequences with precision, pinpoint exact records within seconds using our Sequence Assistant, and leverage the Antibody R&D module to uncover antibody-antigen relationships you might otherwise miss. Stop hunting for data and start driving innovation with confidence. Save your spot: bit.ly/4nqWdex #IPAnalytics #SequenceAnalysis #Biotech #AntibodyDiscovery #PatentData #RAndD #PatSnap #Webinar

🚀 We just got back from Antibody Engineering in Therapeutics 2026! From in silico antibody discovery to hit-to-lead optimization, the field is moving fast. What stood out most? The growing demand for high-quality, validated antibody-antigen data at scale, exactly what we've been building toward. We came away buzzing with insights and ideas, and we can't wait to share what we learned with you. Stay tuned, a deeper dive into our key takeaways is coming soon. Couldn't make it this year? We'd love to connect. Reach out to us directly, let's keep the conversation going. 💬 #AntibodyEngineering #Therapeutics2026 #Biotech #DrugDiscovery #Antibodies

Finding the right material candidates can get messy fast, especially when you’re juggling specific performance requirements, fragmented supplier data, and the need to assess novelty across global IP. Join us for PatSnap Eureka Materials: Enhance Your Solution by Locating the Right Material. 📆 02 June, 2026 🕐 10:00 AM EST | 3:00 PM BST In this session, we’ll show you how to move beyond slow, manual material scouting. Learn how to identify candidates based on your exact performance metrics, streamline procurement by instantly mapping supplier landscapes, and leverage our new formulation agent to bring all your R&D data together. Stop hunting for data and start building better solutions with confidence. Save your spot: bit.ly/3Rn3q3b #IPAnalytics #MaterialsScience #RandD #Innovation #PatentData #SupplyChain #PatSnap #Webinar

We're heading to Basel for Antibody Engineering & Therapeutics Europe 2026! 🇨🇭🔬 Our team, Heather Allen, Ben Coverdale, and Fraser Ghai will be at booth #15, ready to show how PatSnap can accelerate your in silico antibody discovery, from target identification to lead optimization, with the data infrastructure to back every decision. Planning to attend? Drop a comment or message us, we’d love to connect and say hello in person! #AET2026 #Biologics #AssetPrioritization #RiskMitigation #IPStrategy #LifeSciences #PatSnap

We're heading to Basel for Antibody Engineering & Therapeutics Europe 2026! 🇨🇭🔬 Our team, Heather Allen, Ben Coverdale, and Fraser Ghai will be at booth #15, ready to show how PatSnap can accelerate your in silico antibody discovery, from target identification to lead optimization, with the data infrastructure to back every decision. Planning to attend? Drop a comment or message us, we’d love to connect and say hello in person! #AET2026 #Biologics #AssetPrioritization #RiskMitigation #IPStrategy #LifeSciences #PatSnap

It's not just better science driving the GLP-1 revolution, it's smarter strategy. 🧠 Learn how fast-follow innovation is powering the next wave of metabolic therapies, from Pfizer's foundational small-molecule research to cutting-edge programs at AstraZeneca, Merck, and Eli Lilly. 💊 PatSnap's GLP-1 Market Landscape report unpacks the IP strategy, licensing deals, and clinical data behind a $100B therapeutic space. Watch to find out how innovation really scales. Download the full report for free: bit.ly/3PW0IBn #GLP1 #DrugDiscovery #Innovation #PatSnap #Innovation #Ozempic

We've spent nearly two decades building the world's most comprehensive innovation intelligence dataset. Now, we're making it more accessible than ever. We have expanded access to PatSnap Eureka, our agentic AI platform for R&D and IP teams, with free self-serve trial access, new APIs, and Model Context Protocol (MCP) integrations that bring our proprietary data directly into the AI environments your teams already use, including Claude, ChatGPT, and Cursor. Because AI is only as valuable as the data behind it. PatSnap's specialized innovation intelligence layer is designed to power higher-quality outputs where general-purpose models fall short. Read the full update: bit.ly/4dzivWO #AI #InnovationIntelligence #RDStrategy #IPStrategy #EnterpriseAI #PatSnap

The best innovators don't just have great ideas. They have the intelligence to move on them first. 🌍 18,000 enterprises, law firms, and research institutions across 50 countries trust PatSnap to make that happen. Faster insights, smarter decisions, at every stage of the innovation lifecycle. Built on the world's largest innovation dataset, this is what decision-grade innovation intelligence looks like. 👇 #PatSnap #InnovationIntelligence #AI #IPManagement #RandD #Innovation

In May 2024, a rescue dog named Rosie was given months to live. Her owner was told there was nothing more to be done. He didn't accept that. Paul Conyngham had no biology background, no lab, no institution behind him. Just a data engineer's instincts and a love for one dog. Over the next year he taught himself computational genomics from scratch, sequenced Rosie's DNA, and designed something nobody had ever built before: a personalized mRNA cancer vaccine for a dog. 🐶🔬 It worked. Six weeks after her first injection the tumors were shrinking. By January she was jumping fences at the dog park chasing rabbits. But what stayed with us was not the breakthrough. It was the cost of getting there. The months lost to dead ends, the patent wall he hit after two weeks of computation, the right collaborators found only by chance after months of cold emails. There are more people like Paul out there. People with real problems, real capability, and no clear map. To us, that's a problem worth solving. 💡 Read the full story: bit.ly/4uAsemG #PatSnap #Innovation #LifeSciences #mRNA #PaulConyngham

The biopharma investment landscape has never been more complex or more consequential. Patent cliffs. Rising R&D costs. M&A deal values that more than doubled in 2025 to $133B. The science behind an asset is increasingly what separates a strong bet from an expensive mistake. Today, we're announcing that Synapse is now available directly within the FactSet Workstation. Financial professionals can now access biopharma pipeline data, IP positions, clinical activity, and deal intelligence without ever leaving their existing workflow. Read the full announcement: bit.ly/3RrDpzC #PatSnap #FactSet #Synapse #Biopharma #LifeSciencesInvesting

💉 GLP-1 innovation isn't slowing down. We're only just beginning to see the economic and cultural impact of Ozempic and it's generic counterparts. The innovators who stand to benefit most are those who realize Ozempic is just the beginning. Read our latest article to see where the industry leaders are headed next, featuring insights from our GLP Market Landscape Report. 🔗 bit.ly/4tMkA8E #PharmaInnovation #GLP1 #HealthcareTrends #Ozempic

Innovation Spotlight 🚀 This week marks a significant milestone in Canada’s pharmaceutical landscape: the approval of the first generic alternative to Ozempic. This is just the beginning. 🔗 bit.ly/4t9pSu2 As GLP-1 therapies continue to reshape the market, increased competition is set to drive accessibility, pricing dynamics, and innovation across the space. Curious about what’s next? Check out the GLP-1 Market Landscape report in the comments to explore emerging players, pipeline developments, and where the future is headed. #PharmaInnovation #GLP1 #HealthcareTrends #Ozempic